可必特+沐舒坦雾化吸入在支气管扩张并感染的临床观察

Clinical observation of Combivent combined with Mucosolvin aerosol inhalation in the treatment of bronchiectasis complicated with infection

目的观察雾化吸入可必特(复方异丙托溴铵雾化溶液)联合沐舒坦在支气管扩张合并感染的临床疗效。方法我院呼吸科就诊的支气管扩张并感染患者60例,随机分为治疗组和对照组。对照组给予常规治疗,治疗组在此基础上给予雾化吸入可必特联合沐舒坦。观察两组临床疗效及治疗前后肺功能指标变化。结果治疗组的咳嗽,咳痰,发热症状减轻及湿性啰音范围固定的时间少于对照组,肺功能改善程度治疗组明显优于对照组。差异有显著性意义(P<0.05)。结论雾化吸入可必特联合沐舒坦能减少支气管扩张合并感染患者的病程,对其咳嗽、咯痰、肺部湿啰音有明显的改善作用。

Objective To observe the clinical effect of Combivent combined with Mucosolvin aerosol inhalation in the treatment of bronchiectasis complicated with infection. Methods 60 patients with bronchiectasis complicated with infection were randomly divided into the treatment group and the control group. All patients were given conventional treatment,and the treatment group was additionally treated with Combivent combined with Mucosolvin aerosol inhalation. The clinical efficacy and pulmonary function were observed before and after the treatment. Results The symptoms of cough,expectoration,fever and moist rales relieved more significantly in the treatment group than in the control group,and the improvement of lung function was more pronounced in the treatment group than in the control group（ P〈0. 05）. Conclusion Combivent combined with Mucosolvin aerosol inhalation can reduce the course of disease and improve the symptoms of cough,expectoration and moist rales in the treatment of bronchiectasis patients complicated with infection.